%0 Consensus Development Conference
%T ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways).
%A Aguilar-Company J
%A Fernández-Ruiz M
%A García-Campelo R
%A Garrido-Castro AC
%A Ruiz-Camps I
%J Clin Microbiol Infect
%V 24
%N 0
%D Jun 2018
%M 29426804
%F 13.31
%R 10.1016/j.cmi.2017.12.027
%X <B>BACKGROUND: </B>The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies.<BR><B>OBJECTIVE: </B>To review, from an infectious diseases perspective, the safety profile of therapies targeting cell surface receptors and associated signaling pathways among cancer patients and to suggest preventive recommendations.<BR><B>METHODS: </B>Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family.<BR><B>BACKGROUND: </B>Vascular endothelial growth factor (VEGF)-targeted agents (bevacizumab and aflibercept) are associated with a meaningful increase in the risk of infection, likely due to drug-induced neutropaenia, although no clear benefit is expected from the universal use of anti-infective prophylaxis. VEGF tyrosine kinase inhibitors (i.e. sorafenib or sunitinib) do not seem to significantly affect host's susceptibility to infection, and universal anti-infective prophylaxis is not recommended either. Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab or panitumumab) induce neutropaenia and secondary skin and soft tissue infection in cases of severe papulopustular rash. Systemic antibiotics (doxycycline or minocycline) should be administered to prevent the latter complication, whereas no recommendation can be established on the benefit from antiviral, antifungal or anti-Pneumocystis prophylaxis. A lower risk of infection is reported for anti-ErbB2/HER2 monoclonal antibodies (trastuzumab and pertuzumab) and ErbB receptor tyrosine kinase inhibitors (including dual-EGFR/ErbB2 inhibitors such as lapatinib or neratinib) compared to conventional chemotherapy, presumably as a result of the decreased occurrence of drug-induced neutropaenia.<BR><B>CONCLUSIONS: </B>With the exception of VEGF-targeted agents, the overall risk of infection associated with the reviewed therapies seems to be low.